Gsa Capital Partners LLP Verve Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 36,102 shares of VERV stock, worth $194,228. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,102
Previous 203,677
82.27%
Holding current value
$194,228
Previous $994,000
82.39%
% of portfolio
0.01%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
186Shares Held
73.3MCall Options Held
85KPut Options Held
183K-
Alphabet Inc. Mountain View, CA12.3MShares$66.4 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$35.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$26.7 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$22.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$21.5 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $322M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...